| 23-1320 |
GlaxoSmithKline, LLC, et al. v. Superior Court of California, Alameda County |
California |
2024-06-18 |
Denied |
can the consumer's home state assert specific per brand-name-manufacturer due-process generic-drug generic-drugs innovator-liability personal-jurisdiction preemption product-liability specific-jurisdiction warning-label-liability |
When a plaintiff alleges injury from the consumption of a generic drug |
| 23A836 |
GlaxoSmithKline, LLC, et al. v. Superior Court of California, Alameda County |
California |
2024-03-12 |
Presumed Complete |
due-process generic-drugs personal-jurisdiction pharmaceutical-litigation specific-jurisdiction warning-label-liability |
Whether a brand-name pharmaceutical company can be subject to specific personal jurisdiction in a state for warning-label liability claims involving g… |
| 23-453 |
Special Risk Insurance Services, Inc. v. GlaxoSmithKline, LLC |
Third Circuit |
2023-10-30 |
Denied |
civil-rights commission-rights diversity-jurisdiction due-process federalism insurance-broker insurance-broker-commissions property-rights state-law |
Whether the court of appeals exercised its diversity jurisdiction to nullify settled state law by allowing an insured to switch brokers while keeping … |
| 18-803 |
Wendy B. Dolin v. GlaxoSmithKline, LLC, fka SmithKline Beecham Corporation |
Seventh Circuit |
2018-12-21 |
Denied |
clinical-trials drug-labeling drug-manufacturer fda-regulations impossibility-preemption labeling-changes preemption truthful-risks unilateral-labeling-changes unilateral-warning wyeth-v-levine |
Does federal law prevent a drug manufacturer from enhancing its label to reflect truthful risks revealed in its clinical trials when the relevant FDA … |